Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment.
Saved in:
| Title: | Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment. |
|---|---|
| Authors: | Coppinger J; C2N Diagnostics, LLC, St. Louis, MO USA., West T; C2N Diagnostics, LLC, St. Louis, MO USA., Kirmess KM; C2N Diagnostics, LLC, St. Louis, MO USA., Fogelman I; C2N Diagnostics, LLC, St. Louis, MO USA., Ray S; C2N Diagnostics, LLC, St. Louis, MO USA., Aurora S; C2N Diagnostics, LLC, St. Louis, MO USA., Verghese PB; C2N Diagnostics, LLC, St. Louis, MO USA., Braunstein JB; C2N Diagnostics, LLC, St. Louis, MO USA., Yarasheski KE; C2N Diagnostics, LLC, St. Louis, MO USA. |
| Source: | MedRxiv : the preprint server for health sciences [medRxiv] 2025 Apr 07. Date of Electronic Publication: 2025 Apr 07. |
| Publication Type: | Journal Article; Preprint |
| Journal Info: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
